Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--CureDuchenne, a leader in raising awareness and funding research to find a cure for Duchenne muscular dystrophy, congratulates Prosensa Therapeutics BV on its initial public offering. CureDuchenne has been a longtime supporter of the company, providing early-stage funding 10 years ago for Prosensa’s antisense (exon skipping) research that led to the development of drisapersen, a promising novel drug for Duchenne. The U.S. Food and Drug Administration recently granted Breakthrough Therapy designation to drisapersen. Drisapersen has shown promising results in Phase II clinical trials released in early 2013 and CureDuchenne looks forward to seeing Phase III data later this year.
Help employers find you! Check out all the jobs and post your resume.
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--CureDuchenne, a leader in raising awareness and funding research to find a cure for Duchenne muscular dystrophy, congratulates Prosensa Therapeutics BV on its initial public offering. CureDuchenne has been a longtime supporter of the company, providing early-stage funding 10 years ago for Prosensa’s antisense (exon skipping) research that led to the development of drisapersen, a promising novel drug for Duchenne. The U.S. Food and Drug Administration recently granted Breakthrough Therapy designation to drisapersen. Drisapersen has shown promising results in Phase II clinical trials released in early 2013 and CureDuchenne looks forward to seeing Phase III data later this year.
Help employers find you! Check out all the jobs and post your resume.
